转移淋巴结站数对食管鳞癌新辅助治疗后首次远处转移的预测价值
本研究纳入557例接受新辅助治疗及McKeown食管切除+三野淋巴结清扫的食管鳞癌患者,比较病理淋巴结分期与转移淋巴结站数对3年首次远处转移的预测能力。结果显示站数越多远处转移累积发生率越高,站数模型判别力和校准度均略优,每增加一站独立升高风险(sHR 1.460),但需外部验证后方可常规使用。
要点
- 转移淋巴结站数增加与3年首次远处转移风险单调升高相关。
- 站数模型较传统病理淋巴结分期判别力略优(AUC差0.0221)。
- 每增加一个受累站独立升高远处转移风险(sHR 1.460)。
核心结论
- 新辅助治疗及三野淋巴结清扫后,转移淋巴结站数较传统病理淋巴结分期略改善远处转移预测,可作为术后风险分层的辅助指标。
研究设计与样本
- 单中心回顾性研究,纳入2015至2023年557例接受新辅助治疗及McKeown食管切除+三野淋巴结清扫的食管鳞癌患者,比较两个仅淋巴结变量不同的Fine-Gray竞争风险模型。
主要发现
- 3年首次远处转移累积发生率随受累站数增加而升高:0站13.0%,1站19.9%,2站29.6%,3站及以上41.4%(Gray P < 0.001)。
- 站数模型判别力更高(AUC差0.0221;95% CI,0.0092-0.0355),校准度更好(Brier评分差-0.0057;95% CI,-0.0094至-0.0021)。
- 每增加一个受累站独立升高风险(亚分布风险比1.460;95% CI,1.287-1.657;P < 0.001)。
- 在约0.22至0.32的阈值概率范围内,站数模型净获益更优。
临床怎么用
- 在传统病理淋巴结分期基础上,可参考转移淋巴结站数辅助术后远处转移风险分层。
- 常规临床使用前需外部验证。
局限性
- 单中心回顾性设计,结果需外部验证后方可常规应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: After neoadjuvant therapy for esophageal squamous cell carcinoma, pathologic nodal staging counts metastatic nodes without capturing their anatomic distribution and is susceptible to stage migration. We evaluated whether involved lymph node station count improves 3-year distant metastasis prediction beyond conventional nodal staging. METHODS: In 557 patients with esophageal squamous cell carcinoma undergoing neoadjuvant therapy and McKeown esophagectomy with three-field lymph node dissection at a single center from 2015 to 2023, two Fine-Gray competing-risks models differed solely in the nodal variable: pathologic nodal category versus station count. Discrimination, calibration, and clinical utility were cross-validated at 3 years. RESULTS: Three-year cumulative incidence of first distant metastasis increased from 13.0% with 0 involved stations to 19.9%, 29.6%, and 41.4% with 1, 2, and 3 or more stations, respectively (Gray P < 0.001). Station count yielded higher discrimination (area under the curve difference 0.0221; 95% CI, 0.0092-0.0355) and better calibration (Brier score difference -0.0057; 95% CI, -0.0094 to -0.0021). Each additional involved station independently raised risk (subdistribution hazard ratio 1.460; 95% CI, 1.287-1.657; P < 0.001). Net benefit favored station count at threshold probabilities of approximately 0.22 to 0.32. CONCLUSIONS: After neoadjuvant therapy and three-field lymph node dissection for esophageal squamous cell carcinoma, station count provided a monotonic risk gradient and modestly improved distant metastasis prediction over conventional nodal staging. As an adjunct to conventional nodal staging, station count may refine postoperative risk stratification. External validation is required before routine clinical use.
引用
- Hong J, Wang P, Liu X, et al. Metastatic Lymph Node Station Count and Risk of First Distant Metastasis After Neoadjuvant Therapy in Esophageal Squamous Cell Carcinoma. Ann Thorac Surg. 2026. PMID: 42744128. doi:10.1016/j.athoracsur.2026.09.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。